AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28929131
Drug: Dopamine D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2 receptor availability assessed with PET-[18F]fallypride
Trial: 24143890
Drug: Cognitive‐reminiscence therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐reminiscence therapy (six sessions of weekly, individual psychotherapy)
Trial: 21165702
Drug: DAO capsules
RxNorm normalized name: Xymogen Histdao Capsules
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAO capsules
Trial: 18438933
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training program for the musculature of the shoulder, held twice a week for 2 months.
Trial: 11063952
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg orally 3 times a day)
Trial: 28982550
Drug: L-carnitine (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (3000 mg/d)
Trial: 20606833
Drug: d‐ACEIs (enalapril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐ACEIs (enalapril, lisinopril, ramipril)
Trial: 17822879
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with clonidine (15 microg/ml)
Trial: 17822879
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with epinephrine (12.5 microg/ml)
Trial: 10071455
Drug: Granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony stimulating factor (G-CSF)
Trial: 9887063
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (800 micrograms twice daily for 4 weeks)
Trial: 8777366
Drug: Solution B
RxNorm normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution B with 5.5% glucose and 100 mmol Na+
Trial: 7173300
Drug: Nicotine chewing
RxNorm normalized name: nicotine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine chewing gum (Nicorette 4 mg)
Trial: 25193991
Drug: Lucitanib (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucitanib (doses from 5 to 30 mg)
Trial: 21377114
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg BID
Trial: 21377114
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg BID
Trial: 11205195
Drug: 5-fluorouracil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil and folinic acid treatment
Trial: 8939037
Drug: Knowledge about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge about the target's role (active agent vs. passive recipient role)
Trial: 1358243
Drug: Alfuzosin 1
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 1 mg
Trial: 1358243
Drug: Alfuzosin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 2.5 mg
Trial: 2650730
Drug: Alfuzosin 5
RxNorm normalized name: alfuzosin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 5 mg
Trial: 27739231
Drug: DW1029M (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DW1029M (300 mg × 2T twice daily) with losartan (50 mg once daily)
Trial: 19496782
Drug: Locoregional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional treatment (mastectomy or breast conserving surgery with level I‐II axillary clearance) followed by radiation therapy to the whole breast and standard systemic therapy.
Trial: 19496782
Drug: No locoregional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No locoregional treatment, standard systemic therapy given immediately after randomization.
Trial: 19496782
Drug: Locoregional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional treatment (mastectomy or breast conserving surgery)
Trial: 15547162
Drug: Lower in-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower in-treatment left ventricular mass index
Trial: 9113931
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mean dose 18,985 units of lipase per kg per day)
Trial: 8478304
Drug: Dirithromycin 500
RxNorm normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dirithromycin 500 mg once daily
Trial: 11417442
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg four times daily
Trial: 3484503
Drug: Bacterial polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial polysaccharide immune globulin (BPIG) administered intramuscularly at a dose of 0.5-0.6 ml/kg
Trial: 27399735
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi training (two 60‐min sessions each week for three months, plus 30 min self‐practice daily)
Trial: 20805113
Drug: 100 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 U/kg unfractionated heparin (UFH)
Trial: 20805113
Drug: 140 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 U/kg unfractionated heparin (UFH) (historical control)
Trial: 17072885
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet plus conventional therapy
Trial: 13678228
Drug: Keishi-bukuryo-gan (KBG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keishi-bukuryo-gan (KBG) 12 g daily for 4 weeks
Trial: 13678228
Drug: Pentoxifylline (PXF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PXF) 300 mg daily for 4 weeks
Trial: 10997480
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogens (CEE) daily
Trial: 1391559
Drug: amoxicillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin‐clavulanic acid (32 patients)
Trial: 3902679
Drug: Fructose (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (1 g/kg)
Trial: 3902679
Drug: Glucose (1
RxNorm normalized name: Fludeoxyglucose (18F)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose (1 g/kg)
Trial: 30815856
Drug: Mephedrone 150
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mephedrone 150 mg
Trial: 18580334
Drug: Fixed iodine-dose
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed iodine-dose protocol (80 mL Iopamidol-370, 20 seconds injection duration)
Trial: 18580334
Drug: Weight-adjusted iodine-dose
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight-adjusted iodine-dose protocol (1.0 mL/kg, 15 seconds injection duration)
Trial: 18580334
Drug: Weight-adjusted iodine-dose
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight-adjusted iodine-dose protocol
Trial: 18580334
Drug: Fixed iodine-dose
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed iodine-dose protocol
Trial: 16502725
Drug: OKM/A group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKM/A group: omeprazole 20 mg twice a day, clarithromycin 500 mg twice a day, metronidazole 500 mg or amoxicillin 1000 mg twice a day
Trial: 16502725
Drug: OBTM group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBTM group: omeprazole 20 mg twice a day, colloid bismuth subcitrate (de-nol) 120 mg four times a day, tetracycline 500 mg four times a day, metronidazole 500 mg twice or 250 mg four times a day
Trial: 8748321
Drug: Mannitol (2.264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (2.264 g)
Trial: 8748321
Drug: Mannitol tablet
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol tablet
Trial: 31345563
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for distal radius fracture
Trial: 26691278
Drug: Metronidazole 0.75%
RxNorm normalized name: METRONIDAZOLE 0.75% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 0.75% cream BID
Trial: 26691278
Drug: Ivermectin 1%
RxNorm normalized name: IVERMECTIN 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 1% cream QD
Trial: 19648304
Drug: Conventional palpation-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional palpation-guided injection
Trial: 17309916
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline infusion plus NAC (n=111)
Trial: 2569997
Drug: Acrivastine 4
RxNorm normalized name: Acrivastine
DrugBank: Acrivastine (DB09488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acrivastine 4 mg
Trial: 2569995
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatments (Acrivastine and Terfenadine)
Trial: 31758541
Drug: Follitropin alfa
RxNorm normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin alfa 'conventional' dosing arm of the ESTHER‐1 trial
Trial: 25611762
Drug: Voice therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice therapy enhanced by MP4 support (4 sessions)
Trial: 25611762
Drug: Voice therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice therapy without MP4 support (4 sessions)
Trial: 24047450
Drug: Manualized supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized supportive therapy
Trial: 19761535
Drug: Intravenous supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous supplementation of trace elements (Se, Mn, Zn)
Trial: 15819377
Drug: Drug treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatments (glycaemia treatment, lipidaemia treatment, blood pressure lowering, platelet aggregation inhibitors)
Trial: 15819377
Drug: Multifactorial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial treatment (open randomised trial)
Trial: 9571355
Drug: Perindopril (4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4-8 mg daily)
Trial: 9571355
Drug: Carvedilol (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25-50 mg daily)
Trial: 31478415
Drug: GM‐CSF supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF supplementation (0.6 ng/mL)
Trial: 11312014
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue vaccine
Trial: 24741050
Drug: Baclofen (GABABR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (GABABR agonist)
Trial: 25245814
Drug: Diazepam (positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (positive modulator at GABAARs)
Trial: 21254867
Drug: 1% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin phosphate gel applied twice daily and 0.1% adapalene gel applied once daily for 4 weeks (initial treatment) followed by either OD group (adapalene applied once daily) or TW group (adapalene applied once daily on 2 days per week) for 4 weeks (maintenance phase)
Trial: 20368559
Drug: Capecitabine (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (given in two divided daily doses for 14 consecutive days of a 21-day cycle for six cycles)
Trial: 11284783
Drug: Nabumetone 1
RxNorm normalized name: nabumetone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1 g b.d. by mouth for 2 weeks
Trial: 11284783
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg daily for 2 weeks
Trial: 11284783
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no aspirin or NSAIDs for 2 weeks)
Trial: 9261860
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg KDI-792
Trial: 9261860
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg KDI-792
Trial: 20622370
Drug: High-dose-rate intracavitary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate intracavitary radiotherapy (HDR-ICRT) with ovoid separation categorized into 26-35 mm
Trial: 20622370
Drug: High-dose-rate intracavitary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate intracavitary radiotherapy (HDR-ICRT)
Trial: 19027431
Drug: Internet-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based self-help cognitive-behavioral therapy (CBT)
Trial: 19027431
Drug: Group-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based cognitive-behavioral therapy (CBT)
Trial: 16797800
Drug: Capsule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulation
Trial: 12560300
Drug: Atracurium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.5 mg x kg(‐1)) with propofol (2.5 mg x kg(‐1))
Trial: 12560300
Drug: Atracurium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.5 mg x kg(‐1)) with propofol (1.5 mg x kg(‐1))
Trial: 12560300
Drug: Propofol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.5 mg x kg(‐1)) without atracurium
Trial: 11164075
Drug: Pharmacia‐Upjohn 15‐mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacia‐Upjohn 15‐mg, 16‐h patch
Trial: 16083710
Drug: lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamivudine 100 mg/day
Trial: 27080767
Drug: entecavir 0.5
RxNorm normalized name: entecavir 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: entecavir 0.5 mg/day
Trial: 27080767
Drug: standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care (no anti-viral therapy)
Trial: 20720257
Drug: Lysine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine supplementation (1 g lysine/d)
Trial: 18519919
Drug: BAY 63‐2521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 63‐2521 (0.25‐5 mg)
Trial: 18519919
Drug: BAY 63‐2521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 63‐2521 (1 mg)
Trial: 18519919
Drug: BAY 63‐2521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 63‐2521 (5 mg)
Trial: 16154547
Drug: Antidepressant naive
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant naive (AN) MDD subjects
Trial: 16154547
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with antidepressant exposure (AE)
Trial: 8609836
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg/d for 5 days)
Trial: 1576049
Drug: PGI2 5
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGI2 5 ng kg‐1 min‐1 for 6 h daily, 5 days a week for 5 weeks
Trial: 1576049
Drug: PGI2 5
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGI2 5 ng kg‐1 min‐1 for 6 h daily, 5 days a week for 5 weeks + molsidomine 12 mg daily
Trial: 1576049
Drug: Molsidomine 12
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine 12 mg daily
Trial: 21918216
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 756 mg Ca/d
Trial: 21918216
Drug: Additional 650
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional 650 mg Ca/d from dairy or calcium carbonate supplements
Trial: 9093724
Drug: FEC 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC 100 (epirubicin 100 mg/m2)
Trial: 9093724
Drug: FEC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC 50 (epirubicin 50 mg/m2)
Trial: 8245325
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg once daily)
Trial: 31592825
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with ≤1 mL HA filler
Trial: 31592825
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with ≤50 s.U ABO, ≤2 mL HA filler, and ≤1 mL RSB
Trial: 24970885
Drug: Pentoxifylline (PTF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTF) 1200 mg/d
Trial: 23652031
Drug: Progesterone gel
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone gel (80 mg applied daily for 14 days)
Trial: 23652031
Drug: Progesterone cream
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone cream
Trial: 2345268
Drug: Progesterone gel
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone gel
Trial: 17094038
Drug: Antenatal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal treatment with intravenous gammaglobulin (IVIG) and/or corticosteroids
Trial: 19737980
Drug: Liraglutide 0.6
RxNorm normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.6 mg
Trial: 11298254
Drug: Medication information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication information leaflets in addition to verbal information
Trial: 11298254
Drug: Verbal medication
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal medication information by nurse or psychiatrist (Control)
Trial: 7937786
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of the advanced glycation inhibitor aminoguanidine to diabetic patients
Trial: 2908716
Drug: Trimazosin 50
RxNorm normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimazosin 50 mg twice daily
Trial: 2908716
Drug: Trimazosin 100
RxNorm normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimazosin 100 mg twice daily
Trial: 2908716
Drug: Trimazosin 200
RxNorm normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimazosin 200 mg twice daily
Trial: 23639861
Drug: Bowman Birk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowman Birk Inhibitor (BBI) complex
Trial: 21624036
Drug: Propylthiouracil (PTU)
RxNorm normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propylthiouracil (PTU) treatment during pregnancy
Trial: 21624036
Drug: Methimazole/carbimazole (MMI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole/carbimazole (MMI) treatment during pregnancy
Trial: 18400462
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care (CC)
Trial: 1402218
Drug: labetalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol (200 mg t.t.d.)
Trial: 1402218
Drug: acebutolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebutolol (200 mg t.t.d.)
Trial: 1402218
Drug: metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (100 mg t.t.d.)
Trial: 31234665
Drug: Abbreviated schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated schedule with three injections at weekly intervals
Trial: 16390397
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) chemoprophylaxis, daily for 1 year
Trial: 7805428
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ciprofloxacin twice daily for 9 days
Trial: 7805428
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg ciprofloxacin twice daily for 9 days
Trial: 3383985
Drug: Magnesium pyridoxal
RxNorm normalized name: magnesium pyridoxal 5-phosphate glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium pyridoxal 5‐phosphate glutamate (MPPG) 3 x 50 mg for 12 weeks
Trial: 25099545
Drug: Intraduodenal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal protein infusion (hydrolyzed whey) 180 kcal